Vijj Kasemsup

Dr. Vijj Kasemsup


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TAThunyarat Anothaisintawee
Thunyarat Anothaisintawee
Yot TeerawattananonYot Teerawattananon
Yot Teerawattananon
CWChollathip Wiratkapun
Chollathip Wiratkapun
VKVijj Kasemsup
Vijj Kasemsup
ATAmmarin Thakkinstian
Ammarin Thakkinstian

4 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Chanita UnhapipatpongChanita Unhapipatpong
Chanita Unhapipatpong
PSPrapimporn Chattranukulchai Shantavasinkul
Prapimporn Chattranukulchai Shantavasinkul
VKVijj Kasemsup
Vijj Kasemsup
SSSukanya Siriyotha
Sukanya Siriyotha
DWDaruneewan Warodomwichit
Daruneewan Warodomwichit
ATAmmarin Thakkinstian
Ammarin Thakkinstian
The health effects of saturated fat, particularly tropical oil, on cardiovascular disease are unclear. We investigated the effect of tropical oil (palm and coconut oils), lard, and other common vegetable oils (soybean and rice bran oils) that are widely used in tropical and Asian countries on lipid profiles. We performed an umbrella review of meta-analyses and systematic reviews. Electronic databases (Medline, Scopus, Embase, and Cochrane) were searched up to December 2018 without language restriction. We identified nine meta-analyses that investigated the effect of dietary oils on lipid levels. Replacement of polyunsaturated fatty-acid-rich oils (PUFAs) and monounsaturated FA-rich oils (MUFAs) with palm oil significantly increased low-density lipoprotein cholesterol (LDL-c), by 3.43 (0.44–6.41) mg/dL and 9.18 (6.90–11.45) mg/dL, respectively, and high-density lipoprotein cholesterol (HDL-c), by 1.89 (1.23–2.55) mg/dL and 0.94 (−0.07–1.97) mg/dL, respectively. Replacement of PUFAs with coconut oil significantly increased HDL-c and total cholesterol –by 2.27 (0.93–3.6) mg/dL and 5.88 (0.21–11.55) mg/dL, respectively—but not LDL-c. Substituting lard for MUFAs and PUFAs increased LDL-c–by 8.39 (2.83–13.95) mg/dL and 9.85 (6.06–13.65) mg/dL, respectively—but not HDL-c. Soybean oil substituted for other PUFAs had no effect on lipid levels, while rice bran oil substitution decreased LDL-c. Our findings show the deleterious effect of saturated fats from animal sources on lipid profiles. Replacement of unsaturated plant-derived fats with plant-derived saturated fats slightly increases LDL-c but also increases HDL-c, which in turn may exert a neutral effect on cardiovascular health.

16 July 2010 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
PLPattara Leelahavarong
Pattara Leelahavarong
UCUsa Chaikledkaew
Usa Chaikledkaew
SHSuradej Hongeng
Suradej Hongeng
VKVijj Kasemsup
Vijj Kasemsup
YLYoel Lubell
Yoel Lubell
Yot TeerawattananonYot Teerawattananon
Yot Teerawattananon
Background: Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available to severe thalassemic patients. The treatment, however, is very costly, particularly in the context of low and middle income countries, and no studies have been carried out to explore its economic justifiability. This study aimed to estimate the cost-utility of HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for severe thalassemia in Thailand, and to investigate the affordability of HSCT using a budget impact analysis.Methods: A Markov model was used to estimate the relevant costs and health outcomes over the patients' lifetimes taking a societal perspective as recommended by Thailand's health technology assessment guidelines. All future costs and outcomes were discounted at a rate of 3% per annum. Primary outcomes of interest were lifetime costs, quality adjusted life years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in Thai baht (THB) per QALY gained.Results: Compared to BT-ICT, the incremental cost-effectiveness ratio increased with patient age from 80,700 to 183,000 THB per QALY gained for related HSCT and 209,000 to 953,000 THB per QALY gained for unrelated HSCT among patients aged 1 to 15 years (US$1= 34 THB). The governmental budget impact analysis showed that providing 200 related HSCT to patients aged 1 to 10 years, in accordance with the current infrastructure limitations, would initially require approximately 90 million additional THB per year.Conclusions: At a societal willingness to pay of 100,000 THB per QALY gained, related HSCT was likely to be a cost-effective and affordable treatment for young children with severe thalassemia in Thailand.